Growth Hormone Release Inhibiting Hormone: Actions on Thyrotrophin and Prolactin Secretion after Thyrotrophin-releasing Hormone

D. CARR, A. GOMEZ-PAN, D. R. WEIGHTMAN, V. C. M. ROY, R. HALL, G. M. BESSER, M. O. THORNER, A. S. MCNEILLY, A. V. SCHALLY, A. J. KASTIN, D. H. COY

British Medical Journal, 1975, 3, 67-69

Summary

The hypothalamic tetradecapeptide growth hormone release inhibiting hormone (GH-RIH) blocked the thyrotrophin response to thyrotrophin-releasing hormone (TRH) in normal people and in patients with primary hypothyroidism. This inhibition was dose related. The TRH-induced prolactin release was not affected by GH-RIH. This dissociation of the thyrotrophin and prolactin responses to TRH by GH-RIH suggests that there are different mechanisms for release of thyrotrophin and prolactin and that only the former is affected by GH-RIH.

Introduction

Since synthetic ovine growth hormone release inhibiting hormone (GH-RIH) became available it has been shown to inhibit the release of several hormones from the pituitary,¹⁻³ the pancreas, and the gastrointestinal tract.⁴⁻⁶ Inhibition of the thyrotrophin response to thyrotrophin-releasing hormone (TRH) by GH-RIH was suggested by preliminary experiments¹ and has since been verified.⁷⁻⁹ We further examined the effects of short-term infusions of GH-RIH on basal thyrotrophin levels and on TRH-induced release of thyrotrophin and prolactin in normal people and in patients with primary thyroid failure.

Endocrine Unit, Department of Medicine, University of Newcastle upon Tyne, Newcastle upon Tyne NE1 4LP

D. CARR, M.B., M.R.C.P., Senior Registrar in Medicine (Present appointment: Consultant Physician, North Tees General Hospital, Stockton on Tees)

A. GOMEZ-PAN, M.D., Research Associate in Medicine

D. R. WEIGHTMAN, Technician

V. C. M. ROY, M.B., B.S., Research Fellow

R. HALL, M.D., F.R.C.P., Professor of Medicine

Medical Professorial Unit, St. Bartholomew's Hospital, London

G. M. BESSER, M.D., F.R.C.P., Professor of Endocrinology

M. O. THORNER, M.B., M.R.C.P., Research Lecturer in Medicine

A. S. MCNEILLY, PH.D., Research Lecturer in Chemical Pathology

Veterans Administration Hospital and Tulane University School of Medicine, New Orleans, Louisiana, U.S.A.

A. V. SCHALLY, PH.D., Professor of Medicine

A. J. KASTIN, M.D., Professor of Medicine

D. H. COY, PH.D., Assistant Professor of Medicine

Patients and Methods

Six healthy men aged 27-42 years with no evidence of pituitary or thyroid disease and three patients with varying degrees of primary hypothyroidism¹⁰ gave their informed written consent to the study.

The cyclic tetradecapeptide GH-RIH was synthesized and purified as described by Coy *et al.*¹¹ Serum TSH was measured by a double antibody radioimmunoassay¹² using M.R.C. 68/38 as standard and National Pituitary Agency thyrotrophin for iodination. Serum prolactin was estimated by a specific double antibody radioimmunoassay¹³ using a rabbit antihuman prolactin antiserum and purified human pituitary prolactin as standard and for iodination. Serum protein-bound iodine (P.B.I.) was measured by the Technicon AutoAnalyzer and residual binding capacity of serum by the Thyopac-3 method (Radiochemical Centre, Amersham); the free thyroxine index (F.T.I.) was calculated from these values. Serum thyroxine (T-4) was measured by the Thyopac-4 method (Radiochemical Centre, Amersham) and serum triiodothyronine (T-3) estimated by radioimmunoassay of unextracted serum.¹⁴ The data were analysed statistically using Student's *t* test (two tailed).

EXPERIMENTAL DESIGN

All studies were started between 7 and 9 a.m., with the subjects recumbent after an overnight fast. Forearm venous cannulae for blood sampling and infusions were inserted 30 minutes before the start of the studies. A constant rate infusion pump was used to administer GH-RIH and the control saline infusions. The normal volunteers all underwent the following procedures: (a) infusion of GH-RIH 1000 µg alone over 75 minutes; (b) infusion of normal saline (40 ml) over 75 minutes with TRH 200 µg given as a 2-ml intravenous bolus at 15 minutes; (c) infusion of GH-RIH 100 µg over 75 minutes with TRH 200 µg intravenous bolus at 15 minutes; (d) infusion of GH-RIH 1000 µg over 75 minutes with TRH 200 µg intravenous bolus at 15 minutes, and (e) infusion of GH-RIH 1000 µg over 75 minutes with TRH 800 µg intravenous bolus at 15 minutes.

Procedures *b*, *c*, and *d* were performed in random order using a crossover design and *a* and *e* were performed later. At least one week elapsed between procedures. Blood sampling began 15 minutes before the infusion started and continued at intervals for 120 minutes.

Three hypothyroid patients with raised thyrotrophin levels received TRH 200 µg as an intravenous bolus with and without GH-RIH as in procedures *b* and *d*. The order of tests was randomized and one week elapsed between tests. Clinical and biochemical details of these patients are shown in the table.

Results

NORMAL SUBJECTS

No significant fall was detected in basal thyrotrophin levels in the normal men undergoing GH-RIH infusions, though very small

Clinical and Biochemical Details of Three Patients with varying Degrees of Hypothyroidism

Case No.	Sex	Age	Grade	P.B.I. (nmol/l)	Thyopac-3	F.T.I.	Basal TSH (mU/l) [†]	T-4 (nmol/l)	T-3 (nmol/l)
1	M.	28	Subclinical	567	102	7.1	15.0	51.5	0.78
2	F.	34	Mild	213	132	2.0	21.7	20.6	0.78
3	F.	51	Overt	489*	131	4.7	29.5	5.2	Undetectable

*The normal P.B.I. in this patient was due to circulating iodoprotein known to be secreted in Hashimoto's disease.

[†]95% of normal people have TSH levels <6 mU/l.

Conversion: SI to Traditional Units—P.B.I.: 100 nmol/l ≈ 1.27 µg/100 ml. T-4: 1 nmol/l ≈ 0.078 µg/100 ml. T-3: 1 nmol/l ≈ 0.65 ng/ml.

changes in serum thyrotrophin within the normal range may not have been detected in our radioimmunoassay. Thyrotrophin levels did not fall below the limit of detection of the assay in any person.

After a 200- μ g injection of TRH the normal rise in serum thyrotrophin was significantly impaired in all subjects when GH-RIH 1000 μ g was infused (at a rate of 13.3 μ g/min). The lower dose of 100 μ g (at 1.3 μ g/min), which was given to five men, failed to suppress the TRH-mediated thyrotrophin release in one man and in the other four caused a smaller reduction than the higher dose. The mean result in the five normal subjects is shown in fig. 1. For statistical analysis the basal thyrotrophin value was taken as the mean of the values at -15 and 0 minutes and the peak was considered as the mean of those obtained at 35, 40, and 45 minutes. There was a significant difference between the rise in thyrotrophin on the control day (saline infusion) and when GH-RIH 1000 μ g was given ($P < 0.001$) and also when GH-RIH 100 μ g was given ($P < 0.05$). We observed no significant rebound in thyrotrophin levels after stopping the GH-RIH infusion such as has been reported by others.⁸

FIG. 1—Effects of GH-RIH and saline on TRH-mediated thyrotrophin release. Results are mean data ($\pm$ S.E.) from five normal men.

There were no differences in the thyrotrophin increments using 200 μ g or 800 μ g injections of TRH during the high-dose infusion of GH-RIH, but the effect of both doses of TRH on thyrotrophin release was impaired by GH-RIH.

The TRH-mediated prolactin release was not significantly affected by GH-RIH (fig. 2). At a constant infusion rate of GH-RIH of 13.3 μ g/min the prolactin response to 200 or 800 μ g of TRH was almost identical.

FIG. 2—Effects of GH-RIH and saline on TRH-mediated prolactin release. Results are mean data from six normal men.

HYPOTHYROID PATIENTS

The thyrotrophin response to an injection of 200 μ g of TRH was impaired, though not completely abolished, by GH-RIH 1000 μ g over 75 minutes in all three patients with raised basal thyrotrophin levels (fig. 3).

FIG. 3—Effects of GH-RIH and saline on TRH-mediated thyrotrophin release in three patients with primary hypothyroidism.

Discussion

These results confirm our preliminary observation that the thyrotrophin response to TRH is inhibited by GH-RIH¹ and show that a similar inhibition occurs in patients with primary hypothyroidism. They also support observations on human subjects in other studies where different doses of the hormones were used.^{7,8} The degree of inhibition of the thyrotrophin response to TRH depends on the dose of GH-RIH used, being much greater at an infusion rate of 13.3 μ g/min than at a rate of 1.3 μ g/min. This contrasts with the response of growth hormone (GH) in acromegaly, where infusions of GH-RIH at these doses are equally effective.¹⁵ That a higher dose of GH-RIH is necessary to inhibit the thyrotrophin response to TRH than to lower GH perhaps indicates that the interaction with TRH is pharmacological and has no physiological significance. A similar conclusion was reached from an in-vivo study in mice, in which larger amounts of GH-RIH, compared with T-3 on a molar basis, were needed to block the thyrotrophin response to TRH.¹⁶

The use of a higher dose of TRH (800 μ g) did not overcome the inhibitory action of GH-RIH on thyrotrophin release, which counters a suggestion that there is competitive inhibition between GH-RIH and TRH for the same receptor sites on the membrane of the thyrotroph.¹ Similarly, competitive inhibition would not be expected from the results of in-vitro work, which suggests that GH-RIH acts distally to the site of action of cyclic adenosine monophosphate,^{17,18} perhaps inhibiting exocytosis,¹⁹ whereas TRH acts on the membrane adenylyl cyclase system to promote cyclic adenosine monophosphate formation,²⁰ though further studies are required to define the precise site of action of GH-RIH. Recent studies by Vale *et al.*⁹ also support the non-competitive nature of the inhibition of TRH by GH-RIH.

Basal thyrotrophin levels in animals⁹ and normal people are not obviously affected by short-term infusions of GH-RIH. Though this might suggest that basal thyrotrophin secretion does not directly depend on TRH drive longer infusions of GH-RIH are required to investigate this matter further.

Though GH-RIH blocks the thyrotrophin response to TRH it has no effect on the prolactin response to TRH. This dissociation of the thyrotrophin and prolactin responses to TRH by GH-RIH suggests different mechanisms for release of thyrotrophin and prolactin of which only the former is affected by GH-RIH. These responses to TRH may also be dissociated in hyperthyroidism, where the thyrotrophin response is completely abolished but the prolactin response merely blunted.²¹ Again, in isolated thyrotrophin deficiency the prolactin response to TRH was normal when the thyrotrophin response was absent.²²

It may be of interest to use GH-RIH as a pharmacological tool in further studies of TRH action and thyrotrophin secretion,

but it seems unlikely that the effects that we have described here will be important when GH-RIH is considered as treatment in cases of GH excess, though long-term studies are needed in normal people and in those with pituitary disease.

We thank Dr. D. C. Evered for his courtesy in estimating T-3 and T-4 and Dr. H. Friesen for providing the purified human pituitary prolactin. We also acknowledge the financial support of the Scientific and Research Committee of the Newcastle Area Health Authority (Teaching), the Veterans Administration, and Tulane University and the excellent secretarial help of Mrs. M. E. Shepherd.

Requests for reprints should be addressed to Professor R. Hall, Endocrine Unit, Department of Medicine, Royal Victoria Infirmary, Newcastle upon Tyne.

References

- ¹ Hall, R., *et al.*, *Lancet*, 1973, 2, 581.
- ² Hansen, A. P., *et al.*, *British Medical Journal*, 1973, 3, 523.
- ³ Siler, T. M., *et al.*, *Journal of Clinical Endocrinology and Metabolism*, 1973, 37, 632.
- ⁴ Alberti, K. G. M. M., *et al.*, *Lancet*, 1973, 2, 1299.
- ⁵ Mortimer, C. H., *et al.*, *Lancet*, 1974, 1, 697.
- ⁶ Bloom, S. R., *et al.*, *Lancet*, 1974, 2, 1106.
- ⁷ Siler, T. M., *et al.*, *Journal of Clinical Endocrinology and Metabolism*, 1974, 38, 742.
- ⁸ Weeke, J., Hansen, A. P., and Lundbaek, K., *Scandinavian Journal of Clinical and Laboratory Investigation*, 1974, 33, 101.
- ⁹ Vale, W., *et al.*, *Endocrinology*, 1974, 95, 968.
- ¹⁰ Evered, D. C., *et al.*, *British Medical Journal*, 1973, 1, 657.
- ¹¹ Coy, D. H., *et al.*, *Biochemical and Biophysical Research Communications*, 1973, 54, 1267.
- ¹² Hall, R., Amos, J., and Ormston, B. J., *British Medical Journal*, 1971, 1, 582.
- ¹³ McNeilly, A. S., and Hagen, C., *Clinical Endocrinology*, 1974, 3, 427.
- ¹⁴ Hesch, R. D., and Evered, D. C., *British Medical Journal*, 1973, 1, 645.
- ¹⁵ Besser, G. M., *et al.*, *British Medical Journal*, 1974, 1, 352.
- ¹⁶ Bowers, C. Y., *et al.*, *Federation Proceedings*, 1974, 33, 263.
- ¹⁷ Borgeat, P., *Biochemical and Biophysical Research Communications*, 1974, 56, 1052.
- ¹⁸ Labrie, F., *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*, in press.
- ¹⁹ Schofield, J. G., Mira, F., and Orci, L., *Diabetologia*, 1974, 10, 357.
- ²⁰ Labrie, F., *et al.*, *Proceedings of the National Academy of Sciences of the United States of America*, 1972, 69, 283.
- ²¹ Bowers, C. Y., Friesen, H. G., and Hwang, P., *Biochemical and Biophysical Research Communications*, 1971, 45, 1033.
- ²² Sachson, R., *et al.*, *New England Journal of Medicine*, 1972, 287, 972.

Indomethacin—Aspirin Interaction: A Clinical Appraisal

P. M. BROOKS, J. J. WALKER, M. A. BELL, W. W. BUCHANAN, A. R. RHYMER

British Medical Journal, 1975, 3, 69-71

Summary

Plasma profiles of indomethacin after a 50-mg oral dose were constructed in six healthy volunteers before and after a week of aspirin treatment. Aspirin did not interfere with indomethacin plasma levels.

To examine the clinical effect of concurrent indomethacin and aspirin treatment 20 patients with seropositive rheumatoid arthritis were given indomethacin 100 mg/day, aspirin soluble 4 g/day, and the two drugs taken together in random order. Analysis of the clinical indices of inflammation—articular index and mean pain score—and of the efficacy of each treatment showed no significant differences between the three treatment groups.

With the proliferation in the number of anti-rheumatic drugs available, the case for giving two or more non-steroidal anti-inflammatory drugs concurrently remains unproved.

Introduction

There is still controversy about the effect of concurrent aspirin treatment on plasma indomethacin levels, and as aspirin and indomethacin are commonly used together¹ it is important to establish the clinical significance of any interaction. We assessed the effect of aspirin administration on plasma indomethacin

profiles in normal people and also investigated the clinical effect of each drug alone and in combination by a double-blind crossover assessment in 20 patients with rheumatoid arthritis.

Patients and Methods

Profile Study.—After a light breakfast indomethacin 50 mg was given by mouth to six normal people and blood was collected then and at 30, 60, 90, 120, 180, and 240 minutes after ingestion. Soluble aspirin 4 g/day was then given for one week using soluble aspirin 500-mg tablets in four equal doses and the indomethacin 50-mg profile was repeated.

Double-blind Crossover Study.—Twenty patients with seropositive rheumatoid arthritis according to the American Rheumatism Association criteria were also studied. The mean age of the patients was 56.2 years and the mean duration of disease was 8.2 years. The patients were given in random order two-week treatment periods of aspirin and placebo, placebo and indomethacin, and aspirin, and indomethacin. The treatments were randomized using a Latin square matrix. The patients were assessed by a single observer at the same time of day on day 14 of each treatment period. Standard methodology was used for measuring an articular index of joint tenderness,² grip strength in the right and left hand,³ and pain score.²² The patients were given a chart on which they recorded the degree of joint pain each night before they retired to bed.²² At the end of the trial patients were asked to compare the three treatment regimens. For statistical purposes the efficacy ratings were given a total score of 9: 5 for the most preferable, 3 for the next most preferable, and 1 for the least preferable treatment. If two treatments were equal the points available after consideration of the other treatment were divided equally.

Plasma indomethacin levels were measured using the spectrofluorimetric method⁴ of Hucker with the modification described by Emori.⁵ There was no interference with the indomethacin assay when aspirin 10 mg/100 ml or 20 mg/100 ml was added to plasma standards containing 2 µg/ml or 5 µg/ml of indomethacin. The results were analysed statistically using Student's *t* test for paired values.

Results

Profile Study.—The results of the plasma profiles of a 50-mg oral indomethacin dose before and after a seven-day course of aspirin

Centre for Rheumatic Diseases and University Department of Medicine, Royal Infirmary, Glasgow

P. M. BROOKS, F.R.A.C.P., Robins Research Fellow

J. J. WALKER, Medical Student

M. A. BELL, A.I.M.L.T., Senior Technician

W. W. BUCHANAN, F.R.C.P., Professor of Medicine

Merck, Sharp And Dohme Ltd., Hoddesdon, Herts

A. R. RHYMER, M.R.C.P., Clinical Research Physician